Corebridge Financial Inc. Reduces Position in Progyny, Inc. (NASDAQ:PGNY)

Corebridge Financial Inc. decreased its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 12.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,047 shares of the company’s stock after selling 6,192 shares during the period. Corebridge Financial Inc.’s holdings in Progyny were worth $725,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. River Road Asset Management LLC acquired a new position in shares of Progyny in the 4th quarter valued at $25,529,000. Pacer Advisors Inc. grew its position in Progyny by 47.5% during the 4th quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company’s stock worth $63,414,000 after purchasing an additional 1,183,558 shares during the last quarter. Fort Washington Investment Advisors Inc. OH increased its stake in Progyny by 90.1% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock valued at $25,319,000 after purchasing an additional 695,740 shares during the period. Barclays PLC increased its stake in Progyny by 530.4% in the third quarter. Barclays PLC now owns 706,157 shares of the company’s stock valued at $11,835,000 after purchasing an additional 594,140 shares during the period. Finally, Baillie Gifford & Co. raised its holdings in shares of Progyny by 52.2% in the fourth quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company’s stock valued at $22,989,000 after buying an additional 456,853 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Monday, March 31st. Bank of America boosted their target price on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. increased their price target on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Finally, Canaccord Genuity Group lifted their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, February 28th. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Progyny presently has an average rating of “Hold” and an average price target of $23.64.

Progyny Stock Performance

Progyny stock opened at $22.60 on Monday. The company has a market cap of $1.93 billion, a P/E ratio of 38.97, a price-to-earnings-growth ratio of 2.39 and a beta of 1.33. Progyny, Inc. has a one year low of $13.39 and a one year high of $36.36. The business has a fifty day moving average of $22.19 and a two-hundred day moving average of $18.45.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.